How I treat elderly patients with myeloma

被引：35

作者：

Mehta, Jayesh ^{[1
]}

Cavo, Michele ^{[2
]}

Singhal, Seema ^{[1
]}

机构：

[1] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[2] Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

来源：

BLOOD | 2010年 / 116卷 / 13期

关键词：

STEM-CELL TRANSPLANTATION; RELAPSED MULTIPLE-MYELOMA; LENALIDOMIDE PLUS DEXAMETHASONE; HIGH-DOSE CHEMOTHERAPY; QUALITY-OF-LIFE; AUTOLOGOUS TRANSPLANTATION; INITIAL THERAPY; THALIDOMIDE; MELPHALAN; TRIAL;

D O I：

10.1182/blood-2009-10-163329

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The clinical approach to older patients with myeloma has to be modified to take into account comorbidities and the likelihood of higher treatment-related toxicity. Individualization of management and adequate supportive therapy are important to obtain the best response while minimizing adverse effects. Corticosteroids, novel agents, conventional cytotoxic agents, and high-dose chemotherapy with autotransplantation (modalities used in younger patients) are also used in older patients, although the elderly undergo transplantation less frequently. The sequential use of active agents singly and in different combinations has improved response rates and survival of all patients with myeloma, including the elderly. (Blood. 2010;116(13):2215-2223)

引用

页码：2215 / 2223

页数：9

共 47 条

[1]

[Anonymous], BLOOD

[2]

[Anonymous], BLOOD

[3] Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years [J].

Badros, A ;

Barlogie, B ;

Siegel, E ;

Morris, C ;

Desikan, R ;

Zangari, M ;

Fassas, A ;

Anaissie, E ;

Munshi, N ;

Tricot, G .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (03) :600-607

[4] The changing landscape of myeloma therapy [J].

Cavo, M ;

Baccarani, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1076-1078

[5] Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma [J].

Cavo, M ;

Zamagni, E ;

Tosi, P ;

Tacchetti, P ;

Cellini, C ;

Cangini, D ;

de Vivo, A ;

Testoni, N ;

Nicci, C ;

Terragna, C ;

Grafone, T ;

Perrone, G ;

Ceccolini, M ;

Tura, S ;

Baccarani, M .

BLOOD, 2005, 106 (01) :35-39

[6]

Cavo M, 2002, HAEMATOLOGICA, V87, P934

[7] Thalidomide Maintenance in Multiple Myeloma: Certainties and Controversies [J].

Cavo, Michele ;

Pantani, Lucia ;

Tacchetti, Paola ;

Pallotti, Maria Caterina ;

Brioli, Annamaria ;

Petrucci, Alessandro ;

Zamagni, Elena ;

Tosi, Patrizia .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (32) :E186-E187

[8]

Dingli D, 2009, BLOOD, V114, P506

[9]

Durie Brian G M, 2003, Hematol J, V4, P379

[10] Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial [J].

Facon, Thierry ;

Mary, Jean Yves ;

Hulin, Cyrille ;

Benbouker, Lofti ;

Attal, Michel ;

Pegourie, Brigitte ;

Renaud, Marc ;

Guillerm, Jean Luc Harousseau Gaelle ;

Ahletaix, Carine ;

Dib, Mamoun ;

Voillat, Laurent ;

Maisonneuve, Herve ;

Troncy, Jacques ;

Dervaux, Weronique ;

Monconduit, Mathieu ;

Martin, Claude ;

Casassus, Philippe ;

Jaubert, Jerome ;

Jardel, Henry ;

Doyen, Chantal ;

Kolb, Brigitte ;

Anglaret, Bruno ;

Grosbois, Bernard ;

Yakoub-Agha, Ibrahim ;

Mathiot, Claire ;

Avet-Loiseau, Herve .

LANCET, 2007, 370 (9594) :1209-1218

← 1 2 3 4 5 →